Study of calaspargase pegol on blood clotting in pediatric leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how a chemotherapy drug called calaspargase pegol affects blood clotting in children and young adults with leukemia. It will help doctors understand if changes in clotting are common and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 2 to 21.5 years old
- Diagnosed with acute lymphoblastic leukemia or lymphoma
- Will be receiving calaspargase pegol (Cal-PEG) as part of treatment
- No known bleeding or clotting disorders
- No blood thinners taken within 48 hours before the study blood draw
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is checking how long the cancer drug calaspargase stays active in the body. It aims to help doctors understand how to best use this medicine for children and young adults with acute lymphoblastic leukemia or lymphoma.
This study looks at how many children develop high ammonia levels after receiving a cancer medicine called recombinant Erwinia asparaginase. It helps doctors understand side effects and keep patients safe.
This study looks at how the immune system reacts to a chemotherapy drug called PEG asparaginase in children and young adults. Understanding this could help improve treatment for leukemia by managing or reducing allergic reactions.
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
This study looks at why some people develop liver problems while taking asparaginase, a common medicine used to treat newly diagnosed acute lymphoblastic leukemia (ALL). The goal is to use genetic information to better understand and potentially prevent this side effect.
This study looks at how blood sugar changes in children and teens receiving treatment for ALL (a leukemia) or lymphoma. It focuses specifically on effects that may be caused by steroids and a medicine called PEG-asparaginase.
Hear when a new Childhood Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.